| Brief treatment with the glucocorticoid receptor antagonist mifepristone normalises the corticosterone‐induced reduction of adult hippocampal neurogenesis JL Mayer, L Klumpers, S Maslam, ER De Kloet, M Joels, PJ Lucassen Journal of neuroendocrinology 18 (8), 629-631, 2006 | 219 | 2006 |
| Manipulating brain connectivity with δ9-tetrahydrocannabinol: a pharmacological resting state FMRI study LE Klumpers, DM Cole, N Khalili-Mahani, RP Soeter, ET Te Beek, ... Neuroimage 63 (3), 1701-1711, 2012 | 103 | 2012 |
| A brief background on cannabis: From plant to medical indications LE Klumpers, DL Thacker Journal of AOAC International 102 (2), 412-420, 2019 | 98 | 2019 |
| Novel Δ9‐tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects LE Klumpers, TL Beumer, JGC van Hasselt, A Lipplaa, LB Karger, ... British journal of clinical pharmacology 74 (1), 42-53, 2012 | 88 | 2012 |
| Population pharmacokinetic model of THC integrates oral, intravenous, and pulmonary dosing and characterizes short-and long-term pharmacokinetics JAAC Heuberger, Z Guan, OO Oyetayo, L Klumpers, PD Morrison, ... Clinical pharmacokinetics 54, 209-219, 2015 | 77 | 2015 |
| Peripheral selectivity of the novel cannabinoid receptor antagonist TM 38837 in healthy subjects LE Klumpers, M Fridberg, ML de Kam, PB Little, NO Jensen, HD Kleinloog, ... British Journal of Clinical Pharmacology 76 (6), 846-857, 2013 | 76 | 2013 |
| Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ9‐tetrahydrocannabinol‐induced central nervous system and heart rate effects in humans LE Klumpers, C Roy, G Ferron, S Turpault, F Poitiers, JL Pinquier, ... British Journal of Clinical Pharmacology 76 (1), 65-77, 2013 | 30 | 2013 |
| Review of delta‐8‐tetrahydrocannabinol (Δ8‐THC): Comparative pharmacology with Δ9‐THC M Tagen, LE Klumpers British journal of pharmacology 179 (15), 3915-3933, 2022 | 27 | 2022 |
| Subjective Effects of Ethanol, Morphine, Δ9-Tetrahydrocannabinol, and Ketamine Following a Pharmacological Challenge Are Related to Functional Brain Connectivity D Kleinloog, S Rombouts, R Zoethout, L Klumpers, M Niesters, ... Brain connectivity 5 (10), 641-648, 2015 | 14 | 2015 |
| Surinabant, a selective CB (1) antagonist, inhibits THC-induced central nervous system and heart rate effects in humans LE Klumpers, C Roy, G Ferron, S Turpault, F Poitiers, JL Pinquier, ... Br J Clin Pharmacol 76, 65-77, 2013 | 5 | 2013 |
| Pharmacokinetic/pharmaco–dynamic modelling and simulation of the effects of different cannabinoid receptor type 1 antagonists on Δ9‐tetrahydrocannabinol … Z Guan, LE Klumpers, OO Oyetayo, J Heuberger, JMA van Gerven, ... British Journal of Clinical Pharmacology 81 (4), 713-723, 2016 | 3 | 2016 |
| Novel approaches in clinical development of cannabinoid drugs LE Klumpers Leiden University, 2014 | 1 | 2014 |
| Pharmacologic resting state-FMRI: effects of cannabis on functional brain connectivity at rest RP Soeter, LE Klumpers, N Khalili-Mahani, MA van Buchem, ... Annual Meeting of the Organization for Human Brain Mapping, Barcelona, Spain, 2010 | 1 | 2010 |
| Review of delta-8-tetrahydrocannabinol (Delta (8)-THC): Comparative pharmacology with Delta (9)-THC (vol 179, pg 3915, 2022) M Tagen, LE Klumpers BRITISH JOURNAL OF PHARMACOLOGY 180 (1), 130-130, 2023 | | 2023 |
| The Therapeutic Potential of Cannabis and the Endocannabinoid System LE Klumpers, A Hazekamp Principles and Practice of Botanicals as an Integrative Therapy, 393-417, 2019 | | 2019 |
| Sex differences in clinical pharmacology and gender differences in society: How to give an emerging industry a head start L Klumpers ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 255, 2018 | | 2018 |
| Shaping the bright future of the cannabis industry: Because we can L Klumpers, D Thacker, K Franson ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 255, 2018 | | 2018 |
| Does 1+ 1= 3? What science really knows about cannabinoid and terpene effects in humans L Klumpers, K Franson ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 255, 2018 | | 2018 |
| Namisol: een nieuwe formulering van delta⁹-tetrahydrocannabinol met gunstige farmacokinetiek en veelbelovende farmacodynamische effecten LE Klumpers, TL Beumer, JGC van Hasselt, A Lipplaa, LB Karger, ... PW Wetenschappelijk Platform 9 (6), 122-31, 2015 | | 2015 |
| TETRAHYDROCANABINOL TABLET NAMISOL (R): FIRST IN HUMAN PK, PD AND TOLERABILITY LE Klumpers, TL Beumer, LB Karger, A Lipplaa, ML de Kam, ... BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 72 (5), 854-854, 2011 | | 2011 |
Serge A RomboutsLeidenVerified email at lumc.nl
